Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 11Other solid neoplasm 1Breast 1

Conditions

Breast Neoplasms 10163Triple Negative Breast Neoplasms 1042Neoplasms 572Ovarian Neoplasms 560Neoplasm Metastasis 513Colorectal Neoplasms 467Carcinoma, Non-Small-Cell Lung 465Prostatic Neoplasms 439Lung Neoplasms 432Pancreatic Neoplasms 312Melanoma 299Stomach Neoplasms 294Breast Neoplasms, Male 257Motor Activity 252Colonic Neoplasms 238Uterine Cervical Neoplasms 225Endometrial Neoplasms 221Head and Neck Neoplasms 217Carcinoma, Intraductal, Noninfiltrating 217Carcinoma, Renal Cell 191Squamous Cell Carcinoma of Head and Neck 179Sarcoma 175Urinary Bladder Neoplasms 159Brain Neoplasms 155Esophageal Neoplasms 154Breast Carcinoma In Situ 154Lymphedema 148Fatigue 136Carcinoma, Ovarian Epithelial 134Small Cell Lung Carcinoma 128

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Ovarian Cancer × Breast × Clear all
NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
9 enrolled 11 charts
BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡